Good MorningSanta Claus experienced a bit of turbulence in the week leading up to the Christmas holiday but he was able to guide the market up to a new all-time high. The broad market S&P 500 was able to creep up and set a new high on Friday despite weakness in both the blue-chip Dow Jones Industrials and tech-heavy NASDAQ Composite.
The biggest news investors missed last week was the monthly reading of income and spending data. The data shows spending and incomes are on the rise but also a much-hotter than expected increase in inflation. Core inflation accelerated more than expected in November leaving the PCE Price index at the highest level in decades. With the FOMC already moving the timeline for rate hikes forward this news will surely force the committee to do so again.
Featured: 5 Stocks Poised to Soar Under Trump's Presidency (Ad) 
|
Markets | | | Whether you are interested in stocks that have pulled back significantly from their highs or market leaders that could continue running higher next year, there are plenty of intriguing opportunities for investors to consider at this time.
Read the Full Story |
|
From Our PartnersREVEALED: $194 Trillion Trump Market Pattern
Trump fires off a tweet and stocks tank…
He gives a speech and the markets soar…
Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets.
And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance. | | | Click here to discover this exciting new trading pattern. |
|
Stocks | | | If we continue seeing alarming signs of inflation and if nominal yields are held lower, stocks that offer exposure to the safe-haven commodity could have room to run. That’s why it’s a good idea to get familiar with some of the best gold stocks in the market as we head into the new year. Read the Full Story |
|
Markets | | | Twice in the last month, Apple has reached its 52-week high and pulled back both times. This leaves us with the question of whether the third time will be a charm for APPL stock? We believe there are a few reasons that could be the case. Read the Full Story |
|
|
Markets | | | Holiday sales rose at the fastest pace in 17 years, even as shoppers grappled with higher prices, product shortages and a raging new COVID-19 variant in the last few weeks of the season, according to one spending measure Read the Full Story |
|
Politics | | | The latest COVID-19 variant is upending holiday plans for tens of thousands of travelers — but it didn’t do much damage to holiday shopping.
Airlines canceled hundreds more flights Sunday, citing staffing problems tied to COVID-19, as the nation’s travel woes extended beyond Christmas... Read the Full Story |
|
|
Politics | | | Airlines canceled hundreds more flights Sunday, citing staffing problems tied to COVID-19, as the nation's travel woes extended beyond Christmas, with no clear indication when normal schedules would resume.
More than 700 flights entering, leaving or flying within the U.S. were called ... Read the Full Story |
|
Politics | | | Tulane University in New Orleans is delaying the start of its spring semester because of the latest surge in coronavirus cases, and another private school says students must get booster shots before returning Read the Full Story |
|
Politics | | | California health officials say the omicron variant is evident in 50% to 70% of new coronavirus cases in parts of the most populous state heading into the holidays, with the state nearing a total of 5 million virus infections for the pandemic Read the Full Story |
|
Stocks | | |
Connected home fitness equipment maker and platform Peloton (NASDAQ: PTON) stock has been a nasty rollercoaster ride for investors. The popular connected fitness company bounced off $17.70 COVID lows to peak at $171.09 before plunging on the reopening trend back into the $30s. The Company has yet ... Read the Full Story |
|
Stocks | | |
Customer relation management (CRM) software company Salesforce.com (NYSE: CRM) stock has been plunging on its latest top and bottom-line guidance stemming from the fiscal Q3 2022 earnings call. While the fiscal Q3 2021 earnings were very strong, the lowered guidance shocked investors. Arguably, Sa... Read the Full Story |
|
The Early Bird Stock Of The Day Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
